未登录

K

Kathryn Evans

children's cancer institute

H指数:26

被引数:3,016

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The ROR1 antibody-drug conjugate, MK-2140, enhances the efficacy of established drugs in preclinical models of pediatric acute lymphoblastic leukemia

CANCER RESEARCH

IF16.6

2024-03-220

PRE

The menin inhibitor VTP-50469 enhances the in vivo efficacy of established drugs against preclinical models of aggressive infant MLL-r acute lymphoblastic leukemia

MOLECULAR CANCER THERAPEUTICS

IF5.5

2023-12-010

PRE

Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia

IF13.4

2021-04-2422

PREAI

Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells (vol 11, 6211, 2020)

NATURE COMMUNICATIONS

IF15.7

2021-02-190

OAAI

Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells

NATURE COMMUNICATIONS

IF15.7

2020-12-0425

OAAI

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia

IF13.4

2020-10-1627

OAAI

The XPO1 inhibitior, eltanexor, exhibits potent in vivo activity against a broad range of pediatric acute lymphoblastic leukemia subtypes

CANCER RESEARCH

IF16.6

2020-08-152

PRE

Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia

BRITISH JOURNAL OF CANCER

IF6.8

2020-06-152

OAAI

Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia

IF13.4

2019-12-1720

OAAI

The CXCR4 inhibitor X4-136 enhances the in vivo efficacy of established drugs against preclinical models of aggressive pediatric acute lymphoblastic leukemia

MOLECULAR CANCER THERAPEUTICS

IF5.5

2019-12-010

PRE

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

IF6.9

2019-11-01114

OAAI

Rokita, Jo Lynne; Rathi, Komal S.; Cardenas, Maria F.; Upton, Kristen A.; Jayaseelan, Joy; Cross, Katherine L.; Pfeil, Jacob; Egolf, Laura E.; Way, Gregory P.; Farrel, Alvin; Kendsersky, Nathan M.; Patel, Khushbu; Gaonkar, Krutika S.; Modi, Apexa; Berko, Esther R.; Lopez, Gonzalo; Vaksman, Zalman; Mayoh, Chelsea; Nance, Jonas; McCoy, Kristyn; Haber, Michelle; Evans, Kathryn; McCalmont, Hannah; Bendak, Katerina; Boehm, Julia W.; Marshall, Glenn M.; Tyrrell, Vanessa; Kalletla, Karthik; Braun, Frank K.; Qi, Lin; Du, Yunchen; Zhang, Huiyuan; Lindsay, Holly B.; Zhao, Sibo; Shu, Jack; Baxter, Patricia; Morton, Christopher; Kurmashev, Dias; Zheng, Siyuan; Chen, Yidong; Bowen, Jay; Bryan, Anthony C.; Leraas, Kristen M.; Coppens, Sara E.; Doddapaneni, HarshaVardhan; Momin, Zeineen; Zhang, Wendong; Sacks, Gregory, I; Hart, Lori S.; Krytska, Kateryna; Mosse, Yael P.; Gatto, Gregory J.; Sanchez, Yolanda; Greene, Casey S.; Diskin, Sharon J.; Vaske, Olena Morozova; Haussler, David; Gastier-Foster, Julie M.; Kolb, E. Anders; Gorlick, Richard; Li, Xiao-Nan; Reynolds, C. Patrick; Kurmasheva, Raushan T.; Houghton, Peter J.; Smith, Malcolm A.; Lock, Richard B.; Raman, Pichai; Wheeler, David A.; Maris, John M.

Comparison of thio-deoxy-cytidine (TdCyd) and aza-thio-deoxy-cytidine (Aza-TdCyd) in solid and liquid tumor cell lines and PPTC pediatric xenografts

CANCER RESEARCH

IF16.6

2019-07-011

PRE

Pediatric preclinical testing consortium evaluation of the CD123 antibody drug conjugate, IMGN632, against xenograft models of pediatric acute lymphoblastic leukemia

CANCER RESEARCH

IF16.6

2019-07-012

PRE

Pediatric Preclinical Testing Consortium evaluation of the menin inhibitor, VTP-50469, against xenograft models of MLL-rearranged infant acute lymphoblastic leukemia

CANCER RESEARCH

IF16.6

2018-07-010

PRE

Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602

MOLECULAR CANCER THERAPEUTICS

IF5.5

2018-01-010

PRE

Pediatric Preclinical Testing Consortium evaluation of 4′-thio-2′-deoxycytidine (TdCyd) and 5-aza-4′-thio-2′-deoxycytidine (Aza-TdCyd)

MOLECULAR CANCER THERAPEUTICS

IF5.5

2018-01-012

PRE

The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study

MOLECULAR CANCER THERAPEUTICS

IF5.5

2018-01-010

PRE

The nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, OT-82, exhibits in vitro and in vivo efficacy against patient-derived xenograft models of high-risk acute lymphoblastic leukemia

CANCER RESEARCH

IF16.6

2017-07-010

PRE

Inhibition of NAMPT as a novel therapeutic strategy for infant leukemia

CANCER RESEARCH

IF16.6

2017-07-010

PRE

The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury

二肽基肽酶4在四氯化碳诱导的实验性肝损伤中的促纤维化作用

IMMUNOLOGY AND CELL BIOLOGY

IF3

2016-12-2028

PREAI